Read by QxMD icon Read


Hidehiko Saito, Tomomitsu Hotta, Tomoki Naoe
This year, 2018, marks the 60th anniversary of the Asiatic International Society of Hematology founded in 1958 and it seems to be a fitting occasion on which to reflect on our roots of the international cooperation with Asian countries. The Japanese Society of Hematology held the first meeting of the Asiatic International Society of Hematology in 1958 in Nagoya. Hematologists representing at least 10 Asian countries or districts, including Australia, Burma, Ceylon, Hong Kong, India, Indonesia, Korea, Philippines, Taiwan, and Thailand, participated...
October 12, 2018: International Journal of Hematology
Takashi Ashida
"Guidelines for the use of red blood cell products, platelet transfusion concentrates and fresh frozen plasma based on scientific evidence" was published by the Japan Society of Transfusion Medicine and Cell Therapy. Each transfused blood product carries a certain risk of an acute or late adverse event. Hematologists must be familiar with transfusion-associated adverse events, such as transfusion-related acute lung injury, transfusion-associated circulatory overload, post-transfusion graft-versus-host disease, transfusion-transmitted viral infection, etc...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Yimamu Maimaitili, Aki Inase, Yoshiharu Miyata, Akihito Kitao, Yu Mizutani, Seiji Kakiuchi, Yohei Shimono, Yasuyuki Saito, Takashi Sonoki, Hironobu Minami, Hiroshi Matsuoka
Gemtuzumab ozogamicin (GO), the first antibody-drug conjugate (ADC), has attracted the interest of hematologists because more than 90% of acute myeloid leukemia (AML) blasts express its target, CD33. Although GO and subsequently developed ADCs depend on lysosomes for activation, lysosome number and activity in tumor cells has not been well elucidated. In this study, we investigated whether an mTORC1/2 kinase inhibitor, PP242, which was reported to activate lysosomal function, potentiates the cytotoxicity of GO in AML cells...
October 2, 2018: Leukemia Research
Michael D Diamantidis, Vasiliki Gogou, Triantafyllia Koletsa, Simeon Metallidis, Maria Papaioannou
Bone marrow necrosis (BMN) is a condition that can be difficult to diagnose, requiring a hematologist experienced in bone marrow morphology. This diagnostic challenge should alert the clinician of a severe disease or a possible underlying malignancy, either hematological or a solid tumor. We describe the concomitant presence of a primary bone marrow lymphoma (diffuse large B-cell lymphoma-DLBCL), along with an extensive BMN in an HIV patient for the first time in a living individual. HIV infection, BMN and DLBCL presented a multifactorial crossword of molecular events underlying the complex pathophysiology...
October 6, 2018: International Journal of Hematology
Miriam Stenzinger, Halvard Bonig
Leukapheresis is like any other preparative apheresis, except it isn't: Leukapheresis typically takes much longer, larger blood volumes are processed and, consequently, larger ACD-A volumes are administered. Blood component donors and leukapheresis subjects are also quite different populations. Allogeneic donors tend to be younger and many are first-time donors, both of which are risk factors for adverse reactions during blood donation. Moreover, more than half of all leukapheresis collections are performed in patients...
September 15, 2018: Transfusion and Apheresis Science
Heather A Leitch, Rena Buckstein, Nancy Zhu, Thomas J Nevill, Karen W L Yee, Brian Leber, Mary-Margaret Keating, Eve St Hilaire, Rajat Kumar, Robert Delage, Michelle Geddes, John M Storring, April Shamy, Mohamed Elemary, Richard A Wells
In 2008 the first evidence-based Canadian consensus guideline addressing the diagnosis, monitoring and management of transfusional iron overload in patients with myelodysplastic syndromes (MDS) was published. The Canadian Consortium on MDS, comprised of hematologists from across Canada with a clinical and academic interest in MDS, reconvened to update these guidelines. A literature search was updated in 2017; topics reviewed include mechanisms of iron overload induced cellular damage, evidence for clinical endpoints impacted by iron overload including organ dysfunction, infections, marrow failure, overall survival, acute myeloid leukemia progression, and endpoints around hematopoietic stem-cell transplant...
September 19, 2018: Leukemia Research
Olivier Garraud, Anneke Brand, Reinhard Henschler, Tomislav Vuk, Antoine Haddad, Miguel Lozano, Nigar Ertuğrul Örüç, Constantina Politis, Vincenzo de Angelis, Stefan Laspina, Jean-Daniel Tissot
A large body of observations indicate that there is an inconsistent knowledge of Transfusion Medicine among health care professionals as well as inconsistent knowledge in all aspects of the transfusion process, from blood donation to transfusion on the ward. It is obvious to consider that appropriate education in Transfusion Medicine should be achieved in the education of specialists who will prescribe transfusion on a regular basis (hematologists, critical care specialists, anaethesiologists and others.) However,we also believe that education in Transfusion Medicine should also be delivered to almost all other medical specialists who may prescribe blood components...
September 11, 2018: Transfusion and Apheresis Science
Piera Angelillo, Antonella Capasso, Paolo Ghia, Lydia Scarfò
Monoclonal B-cell lymphocytosis (MBL) is defined by the presence of a monoclonal B-cell population in the peripheral blood (PB) at a concentration of <5 × 109 /l and no signs or symptoms of a lymphoproliferative disorder. In around 75% of cases, the immunophenotype of the clonal B-cell expansions is superimposable to that of chronic lymphocytic leukemia (CLL), thus defined "CLL-like". Other cases may coexpress CD19, CD5, bright CD20, and lack CD23 ("atypical CLL"), while others are CD5-negative ("non-CLL")...
September 26, 2018: European Journal of Internal Medicine
Joseph J Shatzel, Matthew O'Donnell, Sven R Olson, Matthew R Kearney, Molly M Daughety, Justine Hum, Khanh P Nguyen, Thomas G DeLoughery
Thrombosis of unusual venous sites encompasses a large part of consultative hematology, and is encountered routinely by practicing hematologists. Contrary to the more commonly encountered lower extremity venous thrombosis and common cardiovascular disorders, the various thromboses outlined in this review have unique presentations, pathophysiology, workup and treatments that all hematologists should be aware of. This review attempts to outline the most up to date literature on cerebral, retinal, upper extremity, hepatic, portal, splenic, mesenteric and renal vein thrombosis, focusing on the incidence, pathophysiology, provoking factors and current recommended treatments for each type of unusual thrombosis to provide a useful and practical review for the hematologist...
September 28, 2018: European Journal of Haematology
Helen M Parsons, Dolly C Penn, Qian Li, Rosemary D Cress, Brad H Pollock, Marcio H Malogolowkin, Ted Wun, Theresa H M Keegan
BACKGROUND: Stagnant outcomes for adolescents and young adults (AYAs) 15-39 years of age with cancer are partly attributed to poor enrollment onto clinical trials. Initiatives have focused on increasing accrual, but changes at the population-level are unknown. We examined patterns of clinical trial participation over time in AYA patients with cancer. PROCEDURE: We utilized medical record data from AYAs in two population-based National Cancer Institute Patterns of Care Studies identified through the Surveillance, Epidemiology and End Results Program...
September 6, 2018: Pediatric Blood & Cancer
Lydia H Pecker, Sarah Kappa, Adam Greenfest, Deepika S Darbari, Robert Sheppard Nickel
OBJECTIVE: To evaluate the impact of an initiative to increase hydroxyurea use among children with sickle cell anemia (SCA) who presented to the emergency department (ED). STUDY DESIGN: This observational cohort study included children with SCA not taking hydroxyurea who presented to the ED with pain or acute chest syndrome and then attended a Quick-Start Hydroxyurea Initiation Project (Q-SHIP) session. A Q-SHIP session includes a hematologist-led discussion on hydroxyurea, a video of patients talking about hydroxyurea, and a direct offer to start hydroxyurea...
October 2018: Journal of Pediatrics
Kaladada I Korubo, Anazoeze J Madu, Helen C Okoye, Benedict Nwogoh
PURPOSE: Novel therapy has dramatically changed the outcome of patients with myeloma. Current National Comprehensive Cancer Network guidelines give bortezomib-based combinations a central role in the management of multiple myeloma (MM). The aim of this survey is to assess the use of bortezomib for the treatment of MM by hematologists practicing in Nigeria. MATERIALS AND METHODS: This is a cross-sectional observational survey. A structured, prevalidated questionnaire was self-administered to different cadres of hematologists...
September 2018: Journal of Global Oncology
F Joseph Simeone, Joel P Harvey, Andrew J Yee, Elizabeth K O'Donnell, Noopur S Raje, Martin Torriani, Miriam A Bredella
OBJECTIVE: To determine the value of low-dose whole-body CT (WBCT) in the management of patients with multiple myeloma (MM) and precursor states. MATERIALS AND METHODS: The study group comprised 116 patients (mean age: 68 ± 11 years, 48% women) who underwent WBCT for the work-up or surveillance of MM or MM precursor disease. WBCTs were reviewed for the presence of MM-related bone disease and incidental findings requiring therapy. The medical records, results from bone marrow aspirations and biopsies and follow-up imaging studies were reviewed to assess the influence of WBCT on patient management...
September 14, 2018: Skeletal Radiology
Michael Kang, Philip Kang
BACKGROUND: Von Willebrand disease (vWD) is the most common hereditary disorder affecting coagulation. Patients with this disorder are at a higher risk of postoperative complications after dental surgery. This article discusses the successful treatment for a patient with vWD undergoing implant therapy. CASE DESCRIPTION: A young 21-year-old patient with vWD lost tooth #30 because of caries and required implant therapy. Through collaboration with a hematologist administering prophylactic desmopressin (DDAVP), the implant surgery was performed without any postoperative complications...
October 2018: Implant Dentistry
Thomas J Humphries, Prasad Mathew
OBJECTIVE: The term cerebral microbleed (CMB) refers to lesions documented as unexpected findings during computed tomography or magnetic resonance imaging examination of the brain. Initially, a CMB was thought to represent hemosiderin-laden macrophages marking an area of a tiny hemorrhage. Recently, histopathologic studies have shown that the structure of a CMB can be variable. To aid in dealing with this finding and judging its clinical significance, this review addresses important aspects of a CMB including the definition, prevalence and incidence in various populations, end-organ damage, associated conditions, and whether any action or treatment by the clinician might be indicated...
September 7, 2018: Current Medical Research and Opinion
Antonio Cuneo, Giovanni Barosi, Romano Danesi, Stefano Fagiuoli, Paolo Ghia, Alfredo Marzano, Marco Montillo, Venerino Poletti, Pierluigi Viale, Pier Luigi Zinzani
The introduction of new therapeutic agents in chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), including the new kinase inhibitor idelalisib, has changed the therapeutic landscape of these diseases. However, the use of idelalisib is associated with a peculiar profile of side effects, which require an optimization of the current approach to prophylaxis and supportive treatment. Moving from the recognition that the abovementioned issue represents an unmet need in CLL and FL, a multidisciplinary panel of experts was convened to produce a consensus document aiming to provide practical recommendations for the management of the side effects during idelalisib therapy for CLL and FL...
September 5, 2018: Hematological Oncology
David P Steensma
Myelodysplastic syndromes (MDS) can be difficult to diagnose, especially when morphological changes in blood and marrow cells are minimal, myeloblast proportion is not increased, and the karyotype is normal. The discovery of more than 40 genes that are recurrently somatically mutated in MDS patients raised hope that molecular genetic testing for these mutations might help clarify the diagnosis in ambiguous cases where patients present with cytopenias and non-diagnostic marrow morphological findings. However, many older healthy individuals also harbor somatic mutations in leukemia-associated driver genes, especially in DNMT3A , TET2 , and ASXL1 - a state termed clonal hematopoiesis of indeterminate potential (CHIP) -- and detection of common aging-associated mutations in a cytopenic patient can cause diagnostic uncertainty...
September 5, 2018: Blood
Annemarie E Fogerty
Thrombocytopenia is a common hematologic issue encountered by obstetricians and hematologists, detected in about 10% of all pregnancies. In the vast majority of cases, the thrombocytopenia will be attributed to gestational thrombocytopenia (GT), where the thrombocytopenia is mild, does not necessitate active management, and does not introduce maternal or fetal bleeding risk. Although GT is common, the specific mechanism responsible for it is not known with certainty, and therefore, differentiating it from other causes of thrombocytopenia can be challenging...
August 23, 2018: Transfusion Medicine Reviews
Xian-Wu Luo, Xue-Qing Du, Jie-Li Li, Xiao-Ping Liu, Xiang-Yu Meng
Background: The refractory/relapsed multiple myeloma (RRMM) remains a big clinical challenge, due to its biological and clinical complexity. Leading hematologists have performed many randomized controlled trials (RCTs) worldwide, and their findings were summarized in a recently published network meta-analysis (NMA) but with certain limitations. Materials and methods: We performed an updated NMA of RCTs related to RRMM treatment, focusing on efficacy measures including the nonresponse rate (NRR), time to progression (TTP), progression-free survival (PFS), and overall survival (OS)...
2018: Cancer Management and Research
Pierre Brissot, Marie-Bérengère Troadec, Olivier Loréal, Eolia Brissot
Iron overload pathophysiology has benefited from significant advances in the knowledge of iron metabolism and in molecular genetics. As a consequence, iron overload nosology has been revisited. The hematologist may be confronted to a number of iron overload syndromes, from genetic or acquired origin. Hemochromatoses, mostly but not exclusively related to the HFE gene, correspond to systemic iron overload of genetic origin in which iron excess is the consequence of hepcidin deficiency, hepcidin being the hormone regulating negatively plasma iron...
August 15, 2018: Transfusion Clinique et Biologique: Journal de la Société Française de Transfusion Sanguine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"